# Research Peptide FAQ — Ipamorelin, NAD+, Thymosin Alpha-1, Tirzepatide — Peptide Med Group > Direct, citation-anchored answers to common questions about ipamorelin, NAD+, thymosin alpha-1, and tirzepatide, drawn from the peer-reviewed literature. Short, citation-anchored answers to the questions readers most often bring to these four research peptides. ## What is ipamorelin? Ipamorelin is a synthetic five-amino-acid peptide that selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells, triggering a short pulse of growth hormone release. It's not approved as a drug anywhere; it's sold as a research chemical. Its only human trial — a 2014 study in patients recovering from bowel surgery — did not show a statistically significant benefit [3]. ## What does ipamorelin do for you? In animals, ipamorelin reliably triggers a single growth-hormone pulse from the pituitary and increases bone growth rate at higher doses [5]. In humans, the evidence is much thinner: the one controlled trial that exists tested recovery after bowel surgery and found no significant benefit over placebo [3]. Community reports describe sleep and recovery effects, but those are self-reported and unverified, not measured in any trial. ## What is ipamorelin peptide? Ipamorelin is a pentapeptide — a chain of five amino acids — engineered from an older growth-hormone-releasing peptide to be more selective. It activates the ghrelin receptor without meaningfully raising cortisol or prolactin, its defining pharmacological trait. Human pharmacokinetic data show a terminal half-life of about two hours [4]. ## What are the risks of ipamorelin? The honest answer is that long-term human risk data doesn't exist — the entire controlled human record is one short perioperative trial [3] and one single-dose pharmacokinetic study [4]. A 28-day rat study of a related ghrelin-receptor agonist, not ipamorelin itself, found dose-dependent heart-muscle damage, the closest thing this receptor class has to a chronic cardiovascular safety signal [2]. Research-grade material also carries no pharmaceutical quality assurance. ## What is NAD supplement used for? NAD+ supplements — usually NMN or NR, since NAD+ itself is poorly absorbed intact — are marketed for energy metabolism and age-related decline. Controlled trials confirm they reliably raise blood NAD+ in a dose-dependent way [7][10]. Some trials show narrower clinical effects too: ten weeks of NMN improved muscle insulin sensitivity in prediabetic women on formal clamp testing [8]. A hard clinical-outcome trial for aging itself doesn't exist yet [6]. ## What is the downside of taking NAD+? The clearest documented downside involves delivery, not the molecule: compounded, injectable NAD+ has been the subject of an FDA Class I recall over bacterial contamination. Infused NAD+ also clears the bloodstream fast, and running an infusion too quickly is linked to nausea, flushing, and chest or abdominal discomfort. On the supplement side, oral NAD+ itself is poorly absorbed, and NMN's regulatory status as a supplement is contested. ## Is it safe to take NAD daily? The precursor trials that exist — testing NMN and NR daily for 8 to 60 days — reported no significant safety issues across a wide dose range, including at the highest doses tested [7][10]. That's a reasonable tolerability signal for the trial durations studied. What's not established is long-term safety beyond those windows, or safety in people with active cancer, given a theoretical concern that NAD+ supports the metabolism of proliferating cells generally. ## Does NAD cause weight gain? No trial on this desk reports NAD+ or its precursors causing weight gain. The clamp study in prediabetic women found no change in body composition after ten weeks of NMN, alongside an improvement in muscle insulin sensitivity [8]. Weight change isn't the endpoint these trials were built to test, so the honest answer is that it hasn't been studied directly, not that it's been ruled out. ## What is thymosin alpha 1? Thymosin alpha-1 is a 28-amino-acid immune-modulating peptide, naturally made by the thymus gland in small amounts. The synthetic drug version, thymalfasin, is approved in more than 35 countries — not including the United States [12]. It acts on dendritic cells and T-cells to help the immune system mature and respond more effectively. ## What does thymosin alpha 1 do? Mechanistically, it activates Toll-like receptors on dendritic cells, driving those cells to mature and present antigens more effectively, which in turn matures T-cells and pushes the immune response toward an infection-fighting profile. In severe COVID-19, it was associated with lower mortality and reversal of T-cell exhaustion markers in a retrospective study [13]. In sepsis, its largest and most rigorous trial — 1,106 patients — found no mortality benefit [11]. ## What is thymosin alpha 1 used for? Internationally, thymalfasin is used for chronic viral infections and as an immune-supportive adjunct in specific clinical settings. It's also studied experimentally — for sepsis, where its largest trial was null [11], and in oncology, as a combination-therapy adjuvant alongside chemotherapy and checkpoint inhibitors in melanoma, liver, and lung cancer [14]. ## Is thymosin alpha 1 FDA-approved? No. Thymosin alpha-1 (thymalfasin) has no FDA marketing approval in the United States, though it is approved as a drug in more than 35 other countries [12]. US use is limited to investigational or compounded contexts. ## What is tirzepatide? Tirzepatide is a synthetic 39-amino-acid peptide that activates two gut-hormone receptors at once — GIP and GLP-1. It's FDA-approved for type 2 diabetes, chronic weight management, and moderate-to-severe sleep apnea in adults with obesity [17]. Of the four compounds on this desk, it carries by far the deepest clinical-trial record. ## How does tirzepatide work? It binds both the GIP and GLP-1 receptors, increasing glucose-triggered insulin release, suppressing glucagon, and slowing stomach emptying — the combination responsible for its blood-sugar and appetite effects. Lab assays show it engages the GIP receptor more strongly than the GLP-1 receptor, with biased signaling at the GLP-1 receptor that favors one internal pathway over another [21]. ## What does tirzepatide do in the body? In the pancreas, it boosts glucose-dependent insulin release and suppresses glucagon. In the gut, it slows stomach emptying, which extends fullness and contributes to nausea as a side effect. In appetite-regulating brain circuits, it reduces food-seeking behavior. In trials, this combination produced weight loss of up to -20.9% at the highest dose over 72 weeks, against -3.1% for placebo [19]. ## What is tirzepatide used for? FDA-approved uses: type 2 diabetes mellitus, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. In a head-to-head Phase 3 trial, it also outperformed semaglutide directly, producing -20.2% weight loss versus -13.7% over 72 weeks [16]. --- This is a citation ledger, not a clinic — we report what the trials found and stop there.